Related references
Note: Only part of the references are listed.CD19 Is a Useful B Cell Marker After Treatment With Rituximab: Comment on the Article by Jones et al
Elena G. Kamburova et al.
ARTHRITIS AND RHEUMATISM (2013)
Correct laboratory approach to APS diagnosis and monitoring
V. Pengo et al.
AUTOIMMUNITY REVIEWS (2013)
Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile
V. Pengo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I
D. M. Wahezi et al.
LUPUS (2013)
The Pathogenesis of the Antiphospholipid Syndrome
Bill Giannakopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Beta2-Glycoprotein I IgG ELISAs
Leonie Pelkmans et al.
PLOS ONE (2013)
Introduction to special theme section: Obesity and the rheumatic diseases
Marian T. Hannan
ARTHRITIS CARE & RESEARCH (2013)
Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis
Seung-Ki Kwok et al.
ARTHRITIS AND RHEUMATISM (2012)
Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome
Michael Mahler et al.
AUTOIMMUNITY REVIEWS (2012)
Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies
M. Mahler et al.
CLINICA CHIMICA ACTA (2012)
Antibodies against domain I of β2-glycoprotein I: the one and only?
L. Pelkmans et al.
LUPUS (2012)
Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?
Laura Andreoli et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Novel Assays of Thrombogenic Pathogenicity in the Antiphospholipid Syndrome Based on the Detection of Molecular Oxidative Modification of the Major Autoantigen β2-Glycoprotein I
Yiannis Ioannou et al.
ARTHRITIS AND RHEUMATISM (2011)
Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope
Bas de Laat et al.
ARTHRITIS AND RHEUMATISM (2011)
β2-Glycoprotein I: a novel component of innate immunity
Cetin Agar et al.
BLOOD (2011)
Interaction of β2-Glycoprotein I with Lipopolysaccharide Leads to Toll-like Receptor 4 (TLR4)-dependent Activation of Macrophages
Patrick Laplante et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Pathogenesis of antiphospholipid syndrome: understanding the antibodies
Pier Luigi Meroni et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
Antibodies to Domain I of β2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS)
A. Banzato et al.
THROMBOSIS RESEARCH (2011)
Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I
Bas de Laat et al.
CURRENT RHEUMATOLOGY REPORTS (2011)
β2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome
Cetin Agar et al.
BLOOD (2010)
Domain I of β2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome
Y. Ioannou et al.
LUPUS (2010)
Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of β2-glycoprotein I
Nicola Pozzi et al.
PROTEIN SCIENCE (2010)
In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β2-glycoprotein I: proof of concept
Y. Ioannou et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study
B. De Laat et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5
Bas de Laat et al.
BLOOD (2007)
Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I - Mutation studies including residues R39 to R43
Yiannis Ioannou et al.
ARTHRITIS AND RHEUMATISM (2007)
Pathogenic anti-β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change
B de Laat et al.
BLOOD (2006)
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
S Miyakis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor
F Fischetti et al.
BLOOD (2005)
IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis
B de Laat et al.
BLOOD (2005)
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome
JH Rand et al.
BLOOD (2004)
Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers - Evidence from atomic force microscopy and functional assay
JH Rand et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Use of single point mutations in domain I of β2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies
GM Iverson et al.
JOURNAL OF IMMUNOLOGY (2002)
Solution structure of human and bovine β2-glycoprotein I revealed by small-angle X-ray scattering
M Hammel et al.
JOURNAL OF MOLECULAR BIOLOGY (2002)
Epitope studies with anti-beta(2)-glycoprotein I antibodies from autoantibody and immunized sources
SW Reddel et al.
JOURNAL OF AUTOIMMUNITY (2000)
Share Paper
